Amedisys Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amedisys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amedisys saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 551,800 shares, an increase of 29.6% from the May 13th total of 425,700 shares. Based on an average daily trading volume, of 190,200 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.7% of the company's stock are short sold.
View Amedisys' Short Interest.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Amedisys.

Amedisys, Inc. (NASDAQ:AMED) released its quarterly earnings data on Tuesday, April, 27th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.43 by $0.11. The health services provider earned $537.10 million during the quarter, compared to analysts' expectations of $544.89 million. Amedisys had a trailing twelve-month return on equity of 28.53% and a net margin of 9.53%. The company's revenue for the quarter was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.05 EPS.
View Amedisys' earnings history.

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMED stock has increased by 52.3% and is now trading at $259.63.
View which stocks have been most impacted by COVID-19.

Amedisys issued an update on its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of 6.850-7.070 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.370. The company issued revenue guidance of $2.30 billion-$2.34 billion, compared to the consensus revenue estimate of $2.30 billion.

11 Wall Street analysts have issued twelve-month price objectives for Amedisys' shares. Their forecasts range from $245.00 to $350.00. On average, they expect Amedisys' share price to reach $289.00 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), LHC Group (LHCG), R1 RCM (RCM), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of AMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.59%), Price T Rowe Associates Inc. MD (4.74%), JPMorgan Chase & Co. (3.59%), Riverbridge Partners LLC (2.79%), Ameriprise Financial Inc. (2.45%) and William Blair Investment Management LLC (2.30%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Dimensional Fund Advisors LP, Prudential Financial Inc., Great Lakes Advisors LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Arabesque Asset Management Ltd, and Putnam Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

AMED stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Ameriprise Financial Inc., Riverbridge Partners LLC, BlackRock Inc., Artemis Investment Management LLP, Intrinsic Edge Capital Management LLC, Northern Trust Corp, and Principal Financial Group Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $259.63.

Amedisys has a market capitalization of $8.46 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.11 on an earnings per share basis.

Amedisys employs 21,000 workers across the globe.

Amedisys was founded in 1982.

The official website for Amedisys is www.amedisys.com.

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]